Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Venafort is an oral dietary supplement developed by Sanifortpharma, a Belgian manufacturer specializing in nutritional products. The formulation is designed to support venous and circulatory health, specifically targeting the relief of heavy legs and improving overall circulation. Its active profile consists of a combination of flavonoids: diosmine, hesperidine, and troxerutine. These compounds function as venotonic and vasculoprotective agents, which help to increase venous tone, reduce capillary permeability, and protect the microcirculation. While Sanifortpharma also produces a topical gel under the same brand name, the oral version is positioned as a food supplement registered with the Federal Agency for the Safety of the Food Chain (FAVV) in Belgium, rather than a pharmaceutical drug undergoing traditional clinical trial phases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Venafort.